Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05644743 | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | not yet recruiting | — | 40 | Chengjun Sui,MDOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT05642338 | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study(WATSEURO2) | recruiting | — | 416 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05331911 | Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors | recruiting | Phase 4 | 500 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05356039 | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer(SQUARE) | recruiting | — | 300 | Umeå UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05620706 | Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05620732 | Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04281667 | Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery(MOBILE2) | active not recruiting | Phase 4 | 604 | Helsinki University Central HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05359393 | A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis(Miracle-1) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05611359 | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer(HOPE-1) | not yet recruiting | N/A | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Nov 10, 2022 | clinicaltrials |
| NCT04078230 | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | recruiting | N/A | 168 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Nov 9, 2022 | clinicaltrials |
| NCT05608213 | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC | recruiting | Phase 3 | 187 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | not yet recruiting | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03747588 | The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer(MIOPP) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04673955 | BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment(BERING-CRC) | recruiting | — | 500 | Pierre Fabre Pharma GmbHINDUSTRY | 2 | Sep 29, 2022 | clinicaltrials |
| NCT05171335 | Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients | enrolling by invitation | Phase 2 | 50 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05541601 | Prospective Cohort for Early Detection of Liver Cancer(Pearl) | recruiting | — | 3,000 | University of OxfordOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05534906 | The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) | recruiting | — | 250 | University of OxfordOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05420480 | Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy | not yet recruiting | N/A | 323 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05239650 | Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | not yet recruiting | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT05323929 | The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma | recruiting | N/A | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04946773 | Deep Liver Phenotyping and Immunology Study(DELPHI) | recruiting | — | 100 | University of OxfordOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05291728 | Screening for Early Gastric Cancer in Shaanxi Province | recruiting | — | 12,500,000 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05270824 | Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03785743 | Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma | recruiting | N/A | 200 | Tongji HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05184400 | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer(CHOCA) | recruiting | — | 500 | Herlev and Gentofte HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05155878 | Prognostic Factors in Periampullary Tumors and Cysts | recruiting | — | 500 | Umeå UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04519905 | Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) | recruiting | N/A | 320 | Fudan UniversityOTHER | 1 | Nov 2, 2021 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04455932 | HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation | recruiting | N/A | 476 | Concord Repatriation General HospitalOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT02073500 | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies(PSM) | recruiting | — | 300 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Dec 9, 2022source: clinicaltrials